Skip to main content

Decoding hypervirulence in carbapenem-resistant Klebsiella pneumoniae: genomic and phenotypic profiling reveals capsular polysaccharide as a key driver of pathogenicity.

The Journal of infectious diseases2026-02-09PubMed
Total: 85.5Rigor: 9Innovation: 9Journal: 8Clinical: 7

Summary

Integrating animal virulence testing with GWAS and transcriptomics, this study shows that capsule production—regulated by rcsA—and hypermucoviscosity are the best discriminators of truly hypervirulent CRKP. A chromosomal SNP signal (rbtT locus) rather than plasmid-borne genes associates with hypervirulence, and capsule/rcsA expression emerge as robust diagnostic biomarkers.

Key Findings

  • Capsule production and hypermucoviscosity robustly discriminate hv-CRKP from other CRKP isolates.
  • GWAS links a chromosomal SNP at the rbtT locus to hypervirulence, while plasmid virulence genes are not significantly associated.
  • rcsA-mediated capsule upregulation enhances resistance to macrophage phagocytosis; capsule production and rcsA are validated as strong diagnostic biomarkers.

Clinical Implications

Laboratories can prioritize capsule/hypermucoviscosity phenotyping and rcsA expression for rapid virulence stratification of CRKP, supporting early source control, isolation, and targeted therapy decisions.

Why It Matters

It reframes hv-CRKP pathogenesis around chromosomally driven capsule control and provides practical biomarkers to distinguish truly hypervirulent strains, directly informing diagnostics and infection control.

Limitations

  • Single animal challenge model (subcutaneous) may not capture systemic sepsis dynamics
  • External clinical validation across diverse geographies and strain backgrounds is pending

Future Directions

Prospective clinical validation of capsule/rcsA biomarkers, development of rapid assays, and exploration of anti-capsule strategies to mitigate hv-CRKP.

Study Information

Study Type
Case-control
Research Domain
Pathophysiology
Evidence Level
IV - Mechanistic and observational comparisons without randomized allocation; translational preclinical evidence with limited clinical correlation.
Study Design
OTHER